Latest Research
All publications from the Cancer3.AI database, newest first.
Patterns of care of gestational trophoblastic disease in Ontario: a population-based study.
Bouchard-Fortier G, et al
Researchers conducted a population-based study examining how gestational trophoblastic disease (GTD), a rare pregnancy-related tumor condition, is diagnosed and treated across Ontario, Canada between 2005 and 2022. Using provincial health databases, the team identified 1,660 molar pregnancies and 385 patients who received chemotherapy for gestational trophoblastic neoplasia (GTN), representing approximately 0.7 molar pregnancies per 1,000 births. The study found that the vast majority of molar pregnancies were managed with suction evacuation, most GTN patients had low-risk disease treated successfully with a single chemotherapy regimen, and the five-year overall survival rate was an impressive 97.9%. Notably, gynecologic oncologists delivered most first-line chemotherapy, and 28% of GTN patients went on to have at least one subsequent birth, demonstrating that fertility can often be preserved. However, the authors caution that the use of administrative databases may have led to under-counting of cases, potentially concealing disparities in care quality and outcomes across the province. The findings strongly support the establishment of mandatory reporting, centralized patient referral, and a dedicated provincial GTD registry to improve care standardization and drive better outcomes for affected patients.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Source →Urethral Diverticulum Mimicking Malignancy on FDG PET/CT.
Ji X, et al
Researchers from a nuclear medicine department report a case of an 80-year-old woman with a history of descending colon cancer who underwent FDG PET/CT imaging for cancer restaging. The scan revealed a hypodense, metabolically active lesion near the urethra that appeared suspicious for malignant disease. Further investigation and correlation with a prior pelvic MRI performed one year earlier confirmed that the lesion was in fact a benign urethral diverticulum, a rare pouch-like outgrowth of the urethral wall, rather than a cancer recurrence or new malignancy. This case highlights an important diagnostic pitfall: urethral diverticula can absorb the radioactive glucose tracer used in PET/CT scans and mimic cancerous lesions, potentially leading to unnecessary anxiety and invasive procedures. Clinicians are advised to include urethral diverticulum in the list of possible diagnoses when evaluating FDG-avid lesions in the urethral region, and to carefully review the patient's history alongside anatomical imaging such as MRI.
Clinical nuclear medicine
Source →Co-occurrence of angioimmunoblastic T-cell lymphoma and aggressive-refractory plasma-cell neoplasm: Two new cases and literature review.
Cox MC, et al
Researchers investigated an exceptionally rare and dangerous combination of two blood cancers: angioimmunoblastic T-cell lymphoma (AITL) and plasma-cell neoplasms such as multiple myeloma occurring in the same patient. The study describes two newly identified patients, including the world's first documented case of primary cutaneous myeloma arising alongside AITL, and combines these with a systematic literature review that identified 16 previously published cases, bringing the total to 18 patients worldwide. Key findings revealed that plasma-cell neoplasms typically appeared at the same time as or shortly after the T-cell lymphoma diagnosis, approximately half of patients had a specific antibody abnormality called IgA paraprotein, and the Epstein-Barr virus was present in cancer cells in only a minority of cases. Outcomes were devastatingly poor, with a median survival of less than two months after the second cancer was diagnosed, highlighting the extreme aggressiveness of this dual malignancy. The authors suggest that the two cancers may share underlying biological mechanisms such as cytokine-driven immune cell activation or even a common cellular origin, rather than being triggered solely by viral infection. This research is critically important for clinicians because it alerts them to monitor AITL patients closely for emerging plasma-cell disease and underscores the urgent need for novel treatment strategies in this setting.
Clinical hematology international
Source →Current Understanding of Lymphoproliferative Disorders.
Junkins-Hopkins JM
A review published in Dermatologic Clinics examines the current understanding of lymphoproliferative disorders, focusing on primary cutaneous T-cell and B-cell lymphomas that can arise at any age. These cancers are distinguished by their clinical presentation, tissue characteristics, and immune cell markers, and accurate diagnosis requires careful correlation of all these features together. A key finding highlighted is that some indolent, low-risk conditions such as lymphomatoid papulosis can look nearly identical under the microscope to aggressive cutaneous T-cell lymphomas, making clinical context essential to avoid overtreating patients. Similarly, certain variants of mycosis fungoides can mimic benign skin conditions, raising the risk of misdiagnosis if clinicians are not vigilant. The review emphasizes that many lymphoproliferative disorders do not require aggressive therapy or extensive staging workup, and that watchful waiting is frequently the most appropriate management strategy. These insights are important for dermatologists and oncologists to minimize unnecessary treatment and improve patient quality of life.
Dermatologic clinics
Source →Sweet's syndrome in acute myeloid leukaemia.
Mon HT, et al
This publication examines Sweet's syndrome, a rare inflammatory skin condition characterized by painful red skin lesions and fever, occurring as a complication in patients with acute myeloid leukaemia (AML). Sweet's syndrome is considered a paraneoplastic phenomenon, meaning it arises as a consequence of the underlying blood cancer rather than from infection or other causes. The report highlights the importance of recognizing this dermatological manifestation in AML patients, as it can precede, coincide with, or signal relapse of the leukaemia. Early identification of Sweet's syndrome in this clinical context is crucial because it may influence treatment decisions and prompt reassessment of the patient's haematological status. Clinicians caring for AML patients should be aware of this association to avoid delays in diagnosis and to initiate appropriate management, which typically involves corticosteroids.
British journal of haematology
Source →